BioDelivery (BDSI) Receives a Buy from Cantor Fitzgerald

By Carrie Williams

In a report released today, Brandon Folkes from Cantor Fitzgerald reiterated a Buy rating on BioDelivery (BDSIResearch Report), with a price target of $8. The company’s shares opened today at $4.62.

Folkes wrote:

“. Post 4Q18, we are reiterating our Overweight rating and our 12-month price target of $8. We view BDSI as a Belbuca execution story, and the company is exceeding its execution goals as well as our expectations. BDSI continues to execute on its commercial plan to drive continued growth of Belbuca, such that we believe investors will be rewarded by the company’s solid execution in 2019 and beyond, which should drive upward earnings revisions and further upside in BDSI’s stock.”

According to TipRanks.com, Folkes is a 2-star analyst with an average return of 0.0% and a 38.9% success rate. Folkes covers the Healthcare sector, focusing on stocks such as Opiant Pharmaceuticals Inc, Eagle Pharmaceuticals Inc, and Collegium Pharmaceutical.

Currently, the analyst consensus on BioDelivery is a Moderate Buy with an average price target of $6.50.

See today’s analyst top recommended stocks >>

The company has a one-year high of $5.21 and a one-year low of $1.70. Currently, BioDelivery has an average volume of 766.1K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

BioDelivery Sciences International, Inc. is a pharmaceutical company, which engages in the development and commercialization of new applications of approved therapeutics to address important unmet medical needs. It focuses on pharmaceutical products in the areas of pain management and addiction.